After Hours Summary: SKX +22%, TEAM +12%, IMPV +5.1%, MXIM +4%, PYPL +3.4% higher and NCR -10%, TACO -6%, ATHN / ISRG -3% lower following earnings/guidance, DRRX -54% after Ph 3 trial resultsAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: SKX +22.3%, TEAM +12%, CAI +6.6%, IMPV +5.1%, MXIM +3.8%, PYPL +3.4%,
Companies trading higher in after hours in reaction to news: AVGR +27.2% (initiates INSIGHT study to evaluate Pantheris Lumivascular Atherectomy System for treating in-stent restenosis in lower extremity arteries), QURE +7.8% (continued momentum), IMDZ +4.5% (confirms the EMA granted Orphan Drug Designation for G100), REN +2.4% (upgraded to Buy from Neutral at Goldman), OAS +1.3% (upgraded to Neutral from Sell at Goldman), HON +1.2% (ahead of earnings), QD +1% (continued momentum), MU +0.9% (attributed to Appaloosa's David Tepper comments at the Robin Hood conference), SYF +0.9% (ahead of earnings), FL +0.8% and DSW +0.5% (SKX sympathy), ON +0.4% (MXIM sympathy), BIDU +0.3% (Baidu.com signed strategic cooperation agreements with China automotive companies BAIC Group and Xiamen King Long United Automotive Industry)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: NCR -10.3%, TACO -5.8%, WERN -4.5% (light volume), PFPT -3.5%, ATHN -3.4%, ISRG -3%, ETFC -2.2% (also to acquire Trust Company of America)
Companies trading lower in after hours in reaction to news: DRRX -54.3% (top-line results from the PERSIST Phase 3 Trial of POSIMIR (SABER-Bupivacaine) did not meet primary efficacy endpoint), BPMX -31% (low cap / thinly traded name; files for $40.25 mln mixed securities shelf offering), AAXN -8.3% (lower after disclosing SEC letter - to review previously filed 10-K/10-Q), CAPR -8.3% (Capricor Therapeutics entered into $14 mln common stock 'at the market offering' sales agreement), DBD -5.7% (following NCR results), CELG -5.6% (announces that the GED-0301 phase III REVOLVE trial in Crohn's disease and the extension trial will discontinue following recommendation from Data Monitoring Committee)